OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	43
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	39
Learning pharmacometric covariate model structures with symbolic regression networks	37
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	36
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	29
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	28
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	22
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	21
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	18
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	15
Current practices for QSP model assessment: an IQ consortium survey	13
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	12
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	12
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	12
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	12
Training the next generation of pharmacometric modelers: a multisector perspective	12
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	11
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	11
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	10
Imputation of missing clock times – application to procalcitonin concentration time course after birth	10
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	9
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	9
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	9
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	9

Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	9
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	8
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
From complex data to biological insight: ‘DEKER’ feature selection and network inference	7
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
Thanks to our Reviewers of 2022!	7
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	7
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	6
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	6
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	6
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	6
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	6
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
Application of machine learning based methods in exposure–response analysis	5
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	5
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	5
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
JPKPD October Special Issue - Commentary	5
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	5
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	5
Correction to: Modeling the acute effects of exercise on glucose dynamics in healthy nondiabetic subjects	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	5
A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics	4
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	4
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	4
A latent variable approach to account for correlated inputs in global sensitivity analysis	4
Computing optimal drug dosing with OptiDose: implementation in NONMEM	4
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	4
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	4
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	4
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	4
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	4
Editor’s note on the themed issue: integration of machine learning and quantitative systems pharmacology	4
Population pharmacokinetic model selection assisted by machine learning	4
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	3
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	3
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	3
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	3
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	3

How drug onset rate and duration of action affect drug forgiveness	3
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV	3
What should patients do if they miss a dose of medication? A theoretical approach	3
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	3
External control arms for rare diseases: building a body of supporting evidence	3
In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	3
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	3
Thanks to our reviewers 2021!	3
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	3
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	2
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	2
Should patients skip late doses of medication? A pharmacokinetic perspective	2
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	2
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	2
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	2
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	2
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	2
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	2
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	2
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	2
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	2
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	2
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	2
An industry perspective on current QSP trends in drug development	2
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	2
Generation and application of avatars in pharmacometric modelling	2
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	2
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	2
Correction to: Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9)	2
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	1
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	1
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics	1
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	1
Optimal control for colistin dosage selection	1
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins	1
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	1
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	1
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	1
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	1
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	1
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	1
A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis	1
Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics	1
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	1
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women	1
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 2. THR-687	1
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	1
Correction: External control arms for rare diseases: building a body of supporting evidence	1
A review of the physiological effects of microgravity and innovative formulation for space travelers	1
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	1
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	1
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach	1
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	1
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	1
Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy	1
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	1
Towards a comprehensive assessment of QSP models: what would it take?	1